ArticleThe journal of allergy and clinical immunology. Global2025
Burden of asthma by severity and exacerbation frequency among adult patients naive to biologic asthma therapy: A Finnish cohort study.
Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort.Journal of personalized medicine · 2026Article
- Mortality Among Adults with Subspecialist-Treated Severe Asthma: A Descriptive Analysis from the Observational CHRONICLE Study.Journal of asthma and allergy · 2026Article
- Impact of Asthma Severity and Exacerbation Frequency on Burden of Disease Related Costs in Finland.Journal of asthma and allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding the disease burden and characteristics of asthmatic patients with frequent exacerbations is important for optimal disease management and outcomes. Asthma, and especially severe uncontrolled asthma, associates with an increased disease burden, but the comparison across asthma severity and exacerbation frequency is largely missing. Objective: We sought to assess the association of asthma severity and exacerbation frequency with medication use, mortality, sick leaves, disability pensions, health care contacts, and comorbidities among Finnish patients with asthma. Methods: National longitudinal retrospective data on adult patients naive to biologic asthma therapy were used to match patients on the basis of age, sex, and region across 4 subgroups (5525 patients in each) of nonsevere or severe asthma with infrequent or frequent exacerbations. The clinical characteristics, mortality rates, and morbidity across the subgroups were analyzed. Results: Exacerbation frequency associated with an increased disease burden regardless of asthma severity. Comorbidities, health care contacts, sick leaves, and disability pensions cumulated in patients with frequent exacerbations, peaking with severe asthma. In patients with severe asthma and frequent exacerbations, the all-cause mortality rate ratio was 1.9-fold ( Conclusions: Despite improved outcomes in asthma over the past decades, a substantial proportion of patients experience frequent exacerbations. These patients are multimorbid and at increased risk of mortality. Exacerbation frequency, rather than asthma severity, seems to be the main factor associated with an increased disease burden. Clinical awareness should be raised to improve the management and outcomes for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.